

# Cybin Files an International Patent Application Covering Psychedelic Delivery Methods

10.12.21

TORONTO,  
CANADA

–

Oct  
12,  
2021

–

[Cybin](#)

Inc.

([NEO:CYBN](#))

(NYSEAMERICAN:CYBN)

the  
“**Company**”),  
a  
biotechnology  
company  
focused  
on  
progressing  
psychedelic  
therapeutics,  
today  
announced  
that  
it  
has  
filed  
an  
international  
patent  
application  
related  
to  
methods  
for  
the

psychedelic  
medications  
by  
inhalation  
and  
devices  
for  
performing  
those  
methods.

The  
application,  
governed  
by  
the  
Patent  
Cooperation  
Treaty  
("PCT"),  
brings  
the  
potential  
to  
obtain

in  
153  
countries.

The  
Company  
believes  
that  
the  
delivery  
of  
psychedelic  
medications  
using  
inhalation  
may  
overcome  
key  
obstacles  
encountered  
by  
traditional  
oral  
drug  
administration.

Company

expects

inhalation

delivery

to

facilitate

optimized

psychedelic

session

timing

compared

to

oral

administration

of

the

same

compounds,

lower

doses

of

psychedelic

therapeutics

while

preserving

providing  
health  
care  
providers  
with  
more  
control  
during  
psychedelic  
sessions.

Filed  
in  
support  
of  
the  
Company's  
[CYB004](#)  
pre-  
clinical  
development  
program,  
the  
PCT  
filing

increase  
the  
Company's  
library  
of  
drug  
delivery  
modalities  
directed  
to  
optimal  
delivery  
of  
psychedelics  
and  
further  
strengthens  
Cybin's  
growing  
IP  
portfolio.

The  
PCT  
filing

support  
for  
future  
research  
programs  
respecting  
various  
systems  
which  
seek  
to  
minimize  
negative  
side  
effects  
in  
psychedelic  
psychotherapy  
patients,  
methods  
that  
enable  
lower  
and  
sub-



without  
impacting  
treatment  
efficacy  
and  
increasing  
the  
long-  
term  
efficacy  
of  
psychedelic  
sessions.

“The  
continued  
progression  
of  
our  
research  
programs  
guides  
our  
discovery  
of

and  
differentiating  
treatment  
approaches.  
Continued  
innovation,  
as  
demonstrated  
by  
our  
expanding  
IP  
portfolio,  
positions  
Cybin  
as  
a  
leading  
innovator  
in  
the  
development  
of  
putative  
psychedelic

a  
variety  
of  
mental  
health  
conditions,”  
said  
Doug  
Drysdale,  
the  
company’s  
CEO.

## About Cybin

Cybin  
is  
a  
leading  
biotechnology  
company  
focused  
on  
progressing  
[psychedelic](#)

utilizing  
proprietary  
drug  
discovery  
platforms,  
innovative  
drug  
delivery  
systems,  
novel  
formulation  
approaches  
and  
treatment  
regimens  
for  
psychiatric  
disorders.

**Cautionary  
Notes  
and  
Forward-  
Looking  
Statements**

in  
this  
press  
release  
constitute  
forward-  
looking  
information.

All  
statements  
other  
than  
statements  
of  
historical  
fact  
contained  
in  
this  
press  
release,  
including,  
without  
limitation,  
statements

future,  
strategy,  
plans,  
objectives,  
goals  
and  
targets,  
and  
any  
statements  
preceded  
by,  
followed  
by  
or  
that  
include  
the  
words  
“believe”,  
“expect”,  
“aim”,  
“intend”,  
“plan”,  
“continue”,

“would”,  
“anticipate”,  
“estimate”,  
“forecast”,  
“predict”,  
“project”,  
“seek”,  
“should”

or

similar

expressions

or

the

negative

thereof,

are

forward-

looking

statements.

Forward

looking

statements

in

this

news

statements  
regarding  
the  
Company's  
development  
of  
innovative  
drug  
delivery  
systems,  
novel  
formulation  
approaches  
and  
potential  
treatment  
regimens  
for  
psychiatric  
disorders  
and  
proprietary  
development  
strategy  
and



medicinal  
psychedelics  
with  
improved  
dosing  
efficacy  
and  
therapeutic  
indices  
to  
address  
unmet  
medical  
needs.

These  
forward-  
looking  
statements  
are  
based  
on  
reasonable  
assumptions  
and

management

of

the

Company

at

the

time

such

statements

were

made.

Actual

future

results

may

differ

materially

as

forward-

looking

statements

involve

known

and

unknown

and  
other  
factors  
which  
may  
cause  
the  
actual  
results,  
performance,  
or  
achievements  
of  
the  
Company  
to  
materially  
differ  
from  
any  
future  
results,  
performance,  
or  
achievements

implied  
by  
such  
forward-  
looking  
statements.

Such  
factors,  
among  
other  
things,  
include:  
implications  
of  
the  
COVID-  
19  
pandemic  
on  
the  
Company's  
operations;  
fluctuations  
in  
general

fluctuations  
in  
securities  
markets;  
expectations  
regarding  
the  
size  
of  
the  
psychedelics  
market;  
the  
ability  
of  
the  
Company  
to  
successfully  
achieve  
its  
business  
objectives;  
plans  
for

social  
and  
environmental  
uncertainties;  
employee  
relations;  
the  
presence  
of  
laws  
and  
regulations  
that  
may  
impose  
restrictions  
in  
the  
markets  
where  
the  
Company  
operates;  
and  
the

set  
out  
in  
the  
Company's  
management's  
discussion  
and  
analysis  
for  
the  
three  
months  
ended  
June  
30,  
2021  
and  
the  
Company's  
listing  
statement  
dated  
November  
9,

are  
available  
under  
the  
Company's  
profile  
on  
[www.sedar.com](http://www.sedar.com)  
and  
with  
the  
U.S.  
Securities  
and  
Exchange  
Commission  
on  
EDGAR  
at  
[www.sec.gov](http://www.sec.gov).  
Although  
the  
forward-  
looking  
statements



this  
news  
release  
are  
based  
upon  
what  
management  
of  
the  
Company  
believes,  
or  
believed  
at  
the  
time,  
to  
be  
reasonable  
assumptions,  
the  
Company  
cannot  
assure

actual  
results  
will  
be  
consistent  
with  
such  
forward-  
looking  
statements,  
as  
there  
may  
be  
other  
factors  
that  
cause  
results  
not  
to  
be  
as  
anticipated,  
estimated

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update

looking  
statements  
of  
beliefs,  
opinions,  
projections,  
or  
other  
factors,  
should  
they  
change,  
except  
as  
required  
by  
law.

Cybin  
makes  
no  
medical,  
treatment  
or  
health

about  
Cybin's  
proposed  
products.  
The  
U.S.  
Food  
and  
Drug  
Administration,  
Health  
Canada  
or  
other  
similar  
regulatory  
authorities  
have  
not  
evaluated  
claims  
regarding  
psilocybin,  
psychedelic  
tryptamine,

or  
other  
psychedelic  
compounds  
or  
nutraceutical  
products.

The  
efficacy  
of  
such  
products  
has  
not  
been  
confirmed  
by  
approved  
research.

There  
is  
no  
assurance  
that  
the

psilocybin,  
psychedelic  
tryptamine,  
tryptamine  
derivatives  
or  
other  
psychedelic  
compounds  
or  
nutraceuticals  
can  
diagnose,  
treat,  
cure  
or  
prevent  
any  
disease  
or  
condition.  
Vigorous  
scientific  
research  
and

are  
needed.  
Cybin  
has  
not  
conducted  
clinical  
trials  
for  
the  
use  
of  
its  
proposed  
products.  
Any  
references  
to  
quality,  
consistency,  
efficacy  
and  
safety  
of  
potential



not  
imply  
that  
Cybin  
verified  
such  
in  
clinical  
trials  
or  
that  
Cybin  
will  
complete  
such  
trials.  
If  
Cybin  
cannot  
obtain  
the  
approvals  
or  
research  
necessary

its  
business,  
it  
may  
have  
a  
material  
adverse  
effect  
on  
Cybin's  
performance  
and  
operations.

*The  
Neo  
Exchange  
Inc.  
has  
neither  
approved  
nor  
disapproved  
the*

*this  
news  
release  
and  
is  
not  
responsible  
for  
the  
adequacy  
and  
accuracy  
of  
the  
contents  
herein.*

**Investor**

**Contacts:**

Tim

Regan/Scott

Eckstein

KCSA

Strategic

Communications

Lisa

M.

Wilson

In-

Site

Communications,

Inc.

[lwilson@insitecony.com](mailto:lwilson@insitecony.com)

## Media

### Contact:

John

Kanakis

Cybin

Inc.

[John@cybin.com](mailto:John@cybin.com)

[PREVIOUS POST](#)

[NEXT POST](#)



5600-100 King St W, Toronto ON  
M5X 1C9  
Investor Contact: [ir@cybin.com](mailto:ir@cybin.com)  
General Contact:  
[info@cybin.com](mailto:info@cybin.com)

**Our Work**

[Development Pipeline](#)

[The Science](#)

[Cybin x Kernel](#)

**Investors**

[Press Releases](#)

[Financials](#)

[Corporate Governance](#)

[Downloads](#)

**About Us**

[Mission](#)

[Team](#)

[News](#)

[Join Us](#)

[Contact](#)

